Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kalena Marti"'
Autor:
Kok Haw Jonathan Lim, Panagiotis Ntellas, Daniel Anderson, Lilly Simpson, Michael Braun, Marios Adamou, Jorge Barriuso, Katerina Dadouli, Jacqueline Connell, Joseph Williams, Theodora Germetaki, Deirdre Lehwald, Niall Fitzpatrick, Mark Cutting, Danielle McCool, Jurjees Hasan, Saifee Mullamitha, Kalena Marti, Mark Saunders, Konstantinos Kamposioras
Publikováno v:
Cancers, Vol 15, Iss 4, p 1226 (2023)
The COVID-19 pandemic has resulted in unprecedented changes to the lives of patients with cancer. To evaluate the impact of the COVID-19 pandemic on the mental health and well-being of patients with colorectal cancer, we conducted a prospective longi
Externí odkaz:
https://doaj.org/article/aec9912d1c644106ab12488a5032094d
Autor:
Gordon C. Jayson, Cong Zhou, Alison Backen, Laura Horsley, Kalena Marti-Marti, Danielle Shaw, Nerissa Mescallado, Andrew Clamp, Mark P. Saunders, Juan W. Valle, Saifee Mullamitha, Mike Braun, Jurjees Hasan, Delyth McEntee, Kathryn Simpson, Ross A. Little, Yvonne Watson, Susan Cheung, Caleb Roberts, Linda Ashcroft, Prakash Manoharan, Stefan J. Scherer, Olivia del Puerto, Alan Jackson, James P. B. O’Connor, Geoff J. M. Parker, Caroline Dive
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Identification of response biomarkers is a key step towards the development of personalised care. Here, Jayson et al. identify plasma Tie2 as a biomarker for the response of the tumor vasculature to anti-angiogenics in patients with metastatic colore
Externí odkaz:
https://doaj.org/article/51bffec067d642f8a6e2d9a8af7b2752
Autor:
Mohammed Alani, Saifee Mullamitha, Nooreen Alam, Konstantinos Kamposioras, Michael Braun, Jurjees Hasan, Joanne Collins, Lauren Bayles, Jennifer King, Mark N. K. Saunders, Kalena Marti, Joseph B. Williams, Spencer Finch, Sophina Mahmood, Jorge Barriuso, Kok Haw Jonathan Lim
Publikováno v:
Clinical Colorectal Cancer
Background Since the beginning of the COVID-19 pandemic, multiple changes to the provision of cancer care have been introduced to maximise patient safety and protect staff. We aimed to identify factors influencing clinicians’ decision on treatment
Autor:
Jacqueline Connell, Konstantinos Kamposioras, Jorge Barriuso, Michael Braun, Mark P Saunders, Daniel M. Anderson, Jurjees Hasan, Mark Cutting, Lilly Simpson, Kalena Marti, Danielle McCool, Saifee Mullamitha, Victoria Lavin, Kok Haw Jonathan Lim
Publikováno v:
Clinical Colorectal Cancer
Kamposioras, K, Saunders, M, Lim, K H J, Marti, K, Anderson, D, Cutting, M, McCool, D, Connell, J, Thompson, L, Hasan, J, Braun, M, Lavin, V, Mullamitha, S & Barriuso, J 2020, ' The impact of changes in service delivery in patients with colorectal cancer during the initial phase of the COVID-19 pandemic ', Clinical Colorectal Cancer, vol. 0, 0, pp. 0 . https://doi.org/10.1016/j.clcc.2020.11.006
Kamposioras, K, Saunders, M, Lim, K H J, Marti, K, Anderson, D, Cutting, M, McCool, D, Connell, J, Thompson, L, Hasan, J, Braun, M, Lavin, V, Mullamitha, S & Barriuso, J 2020, ' The impact of changes in service delivery in patients with colorectal cancer during the initial phase of the COVID-19 pandemic ', Clinical Colorectal Cancer, vol. 0, 0, pp. 0 . https://doi.org/10.1016/j.clcc.2020.11.006
Background The COVID-19 pandemic has imposed significant changes in cancer service delivery resulting in increased anxiety and distress in both patients and clinicians. We aimed to investigate how these changes have been perceived by patients diagnos
Autor:
Mark P Saunders, Jacqueline Connell, Daniel M. Anderson, Lilly Simpson, Jorge Barriuso, Saifee Mullamitha, Konstantinos Kamposioras, Kok Haw Jonathan Lim, Michael Braun, Mark Cutting, Danielle McCool, Jurjees Hasan, Victoria Lavin, Kalena Marti
Publikováno v:
Journal of Clinical Oncology. 39:28-28
28 Background: Increased levels of anxiety and distress in both patients and physicians have been reported in response to the significant impact COVID-19 has on cancer service delivery globally. We aimed to investigate how these changes have been per
Autor:
Pablo Maroto, Torgrim Tandstad, Paul Hutton, Aude Flechon, Breda Škrbinc, Dirk Klingbiel, Matthew Wheater, Caroline Chau, Olof Ståhl, Jörg Beyer, Silke Gillessen, Jonathan Shamash, Brigitte Laguerre, Edurne Arriola, Klaus Peter Dieckmann, Stefanie Fischer, Anja Lorch, Kalena Marti, Umberto Basso, Emilio Porfiri, Gabriella Cohn-Cedermark, Jorge Aparicio
Publikováno v:
Fischer, S, Tandstad, T, Wheater, M, Porfiri, E, Fléchon, A, Aparicio, J, Klingbiel, D, Skrbinc, B, Basso, U, Shamash, J, Lorch, A, Dieckmann, K-P, Cohn-Cedermark, G, Ståhl, O, Chau, C, Arriola, E, Marti, K, Hutton, P, Laguerre, B, Maroto, P, Beyer, J & Gillessen, S 2017, ' Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 35, no. 2, pp. 194-200 . https://doi.org/10.1200/JCO.2016.69.0958
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Purpose Adjuvant carboplatin is one of three management strategies that may follow inguinal orchiectomy in clinical stage I seminoma. However, little is known about the outcome of patients who experience a relapse after such treatment. Patients and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12e87a4769b8d9fb8ed38f433d1d341
https://doi.org/10.5167/uzh-130814
https://doi.org/10.5167/uzh-130814
Autor:
Hamid Y Sheikh, I. Webster, Ram Sundar, Neil A Bayman, Clara Chan, K. Rammohan, R. Shah, Z. Queen, Kalena Marti, Sco Taggart
Publikováno v:
Lung Cancer. 115:S13-S14
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 8:283-293
The prototypic anti-angiogenic agents, VEGF inhibitors, are increasingly used in clinical practice to treat a variety of tumours. Although generally well tolerated, their toxicities can be significant or occasionally life threatening. The ability to
Autor:
Andrew R Clamp, Gordon C Jayson, Alan Jackson, James P B O'Connor, Ross A. Little, Caleb Roberts, Susan Cheung, Mark P Saunders, Prakash Manoharan, Nerissa Mescallado, Geoff J M Parker, Cong Zhou, Yvonne Watson, Caroline Dive, Laura Horsley, Alison Backen, Danielle Shaw, Juan W. Valle, Kalena Marti, Kathryn Simpson
Publikováno v:
Journal of Clinical Oncology. 35:11521-11521
11521 Background: VEGF inhibitor (VEGFi) use is compromised by lack of predictive/ response biomarkers. Previously, we identified plasma Tie2 (pTie2) as a vascular response biomarker (VRB) for bevacizumab (bev) in ovarian cancer (OC). Here, we applie
Autor:
Lim, Kok Haw Jonathan1 (AUTHOR) jonathan.lim@doctors.org.uk, Ntellas, Panagiotis2 (AUTHOR), Anderson, Daniel3 (AUTHOR), Simpson, Lilly1 (AUTHOR), Braun, Michael1 (AUTHOR), Adamou, Marios4 (AUTHOR), Barriuso, Jorge1,5,6 (AUTHOR), Dadouli, Katerina7 (AUTHOR), Connell, Jacqueline1 (AUTHOR), Williams, Joseph1,8 (AUTHOR), Germetaki, Theodora1 (AUTHOR), Lehwald, Deirdre1 (AUTHOR), Fitzpatrick, Niall3 (AUTHOR), Cutting, Mark1 (AUTHOR), McCool, Danielle1 (AUTHOR), Hasan, Jurjees1 (AUTHOR), Mullamitha, Saifee1 (AUTHOR), Marti, Kalena1 (AUTHOR), Saunders, Mark9 (AUTHOR), Kamposioras, Konstantinos1 (AUTHOR) jonathan.lim@doctors.org.uk
Publikováno v:
Cancers. Feb2023, Vol. 15 Issue 4, p1226. 15p.